In our corresponding report of clinical outcomes, we found withmoderate to high certainty that patients treated with MCO dialysis had lowerrates of infection, higher quality of life scores, less fatigue, lower symptomburden, and reduced erythropoietin resistance and iron use, all of which areconsistent with the enhanced large middle-molecule clearance described here.3 This evidence concerns the gene EPO and infection.